/
Monitoring and Modifying Treatment in PAH Monitoring and Modifying Treatment in PAH

Monitoring and Modifying Treatment in PAH - PowerPoint Presentation

briana-ranney
briana-ranney . @briana-ranney
Follow
346 views
Uploaded On 2018-10-25

Monitoring and Modifying Treatment in PAH - PPT Presentation

Suggested Baseline and Serial Assessment of Patients With PAH Why Modify Targeted PAH Therapy Determinants of Prognosis in PAH Case Study 1 A 47YearOld Man With Heritable PAH HPAH Options to Current Regimen of Inhaled Prostanoid ID: 696312

study pah abbreviations case pah study case abbreviations therapy cont year primary griphon current design patients revisiting treatment

Share:

Link:

Embed:

Download Presentation from below link

Download Presentation The PPT/PDF document "Monitoring and Modifying Treatment in PA..." is the property of its rightful owner. Permission is granted to download and print the materials on this web site for personal, non-commercial use only, and to display it on your personal computer provided you do not modify the materials and that you retain all copyright notices contained in the materials. By downloading content from our website, you accept the terms of this agreement.


Presentation Transcript

Slide1

Monitoring and Modifying Treatment in PAHSlide2

Suggested Baseline and Serial Assessment of Patients With PAHSlide3

Why Modify Targeted PAH Therapy?Slide4

Determinants of Prognosis in PAHSlide5

Case Study 1: A 47-Year-Old Man With Heritable PAH (HPAH)Slide6

Options to Current Regimen of Inhaled ProstanoidSlide7

Recommendations for WHO FC II

PAH PatientsSlide8

Repeat RHC?Slide9

PAH: A Heterogeneous Group of Clinical EntitiesSlide10

Importance of Communication Between Specialist and Primary Care Physician Slide11

Case Study 2: A 51-Year-Old Woman With Scleroderma-Associated PAH (SSc PAH)Slide12

Six Months Later…Slide13

Revisiting the Initial Therapy ChoiceSlide14

Pharmacologic Agents for PAH

3 PathwaysSlide15

The Rationale for Combination TherapySlide16

AMBITIONStudy DesignSlide17

AMBITION Study

Primary Endpoint* ResultsSlide18

Revisiting Therapeutic Decision Made at First Follow-Up VisitSlide19

French Registry

Low-Risk CriteriaSlide20

COMPERA RegistryRisk StratificationSlide21

Summary of 3 European StudiesSlide22

Case Review and Current StatusSlide23

GRIPHON Study DesignSlide24

GRIPHONTitration and DosingSlide25

GRIPHON

Treatment Effect by SubgroupSlide26

Worrisome Features of This CaseSlide27

Take-Home PointsSlide28

AbbreviationsSlide29

Abbreviations (cont)Slide30

Abbreviations (cont)Slide31

Abbreviations (cont)